Wu J.-J.TSEN-FANG TSAI2020-10-222020-10-2220080003-987Xhttps://www.scopus.com/inward/record.uri?eid=2-s2.0-54349108621&doi=10.1001%2farchderm.144.10.1403&partnerID=40&md5=e04bc522c5fd7ed2c118be7757df93dbhttps://scholars.lib.ntu.edu.tw/handle/123456789/517695[SDGs]SDG3acarbose; adalimumab; cyclosporin; efalizumab; etanercept; etretin; glimepiride; glucose; infliximab; metformin; methotrexate; tumor necrosis factor; adult; case report; diabetes mellitus; diabetic patient; disease course; disease exacerbation; drug substitution; drug withdrawal; glucose blood level; human; hyperglycemia; hypoglycemia; infection; injection site reaction; letter; liver toxicity; male; monotherapy; pancreas islet beta cell; pancreas islet cell function; photochemotherapy; priority journal; psoriasis; recurrent disease; rheumatoid arthritis; side effect; skin disease; treatment outcome; unspecified side effect; Adult; Antibodies, Monoclonal; Blood Glucose; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Follow-Up Studies; Humans; Hyperglycemia; Psoriasis; Recurrence; Risk Assessment; Sulfonylurea Compounds; Tumor Necrosis Factor-alphaletter10.1001/archderm.144.10.1403189364182-s2.0-54349108621